INTERCEPT-MDS - Dissecting the cellular crosstalk between the bone marrow microenvironment and hematopoietic stem/progenitor cells (HSPCs) in clonal hematopoiesis of indeterminate potential, myelodysplastic syndromes and secondary acute myeloid leukemia
Research · Klinikum rechts der Isar der TU München. Germany > Munich
1 full-time PhD position
HOST INSTITUTE: Klinikum rechts der Isar der TU München. Germany > Munich
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 30 July 2021 (midnight CEST)
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 953407
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
The Innovative Training Network (ITN) “INTERCEPT-MDS - Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells" is recruiting 1 highly motivated PhD candidate. The offered position is available with a duration of 36 months in the Klinikum rechts der Isar der TU München (Munich, Germany) under the supervision of Prof. Katharina Götze. The position is funded as part of the Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks under the European Commission’s Horizon 2020 programme. MARIE CURIE GRANT AGREEMENT NUMBER: 953407
See more info at: https://ec.europa.eu/research/...
Scientific Project: Dissecting the cellular crosstalk between the bone marrow microenvironment and hematopoietic stem/progenitor cells (HSPCs) in clonal hematopoiesis of indeterminate potential (CHIP), myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML)
Prof. Katharina Götze’s lab (https://med3.mri.tum.de/de/hematopoeitic-stem-cells-and-microenvironment) focuses on interaction between hematopoietic stem and progenitor cells (HSPC) and their bone marrow microenvironment (niche) to identify and target critical pathways directing clonal evolution and enabling survival and expansion of mutated HSPC. The project will dissect the cellular crosstalk between niche and HSPCs in the developmental trajectory from clonal hematopoiesis of indeterminate potential (CHIP) to myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML) with a focus on inflammatory pathways. Using primary patient samples, the PhD candidate will employ a variety of wet lab techniques including single cell (sc)RNA sequencing, ATAC sequencing, multiparameter flow cytometry, spatial resolution by confocal microscopy and CRISPR/Cas editing of primary niche cells, with the ultimate goal of identifying specific triggers of disease progression. To further broaden the expertise of the PhD candidate and support the project, two secondments of 3 months at Dr. Hind Medyouf’s lab (Georg Speyer Haus, Frankfurt, Germany) to employ co-transplantation mouse models and 3 months at GenomeScan B.V. (Leiden, Netherlands) for generation and in-depth analyses of scRNAseq data will be offered as an integral part of the PhD project.
PhD candidates interested in translational cancer research, hematopoiesis, inflammation, leukemia and/or stem cells are encouraged to apply. Prior experience with stem cell assays, flow cytometry, RNA sequencing, bioinformatics or computational biology is highly desirable.